SEC News 8-18-2017 Request to vote on (1) Approval of the Fourth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan to increase the number of shares of common stock available for issuance pursuant to awards under such plan by 40,000,000 shares, to a total of 40,690,800 shares of common stock, and reapproval of the material terms of the plan’s performance goals in order to allow certain awards granted thereunder to be eligible for exemption from the $1,000,000 deduction limit imposed by Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Incentive Plan Proposal”). (2) Authorization of the board of directors, in its discretion but prior to the annual meeting of our stockholders in 2018, to amend the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for- 10 to 1-for-25, such ratio to be determined by the board of directors (the “Reverse Stock Split Proposal”).
They are doing this due to the share price being so low at present. It does not mean that they will actually make it immediately effective; it just give them the option in the future to perform the Reverse split since it would be already approved like they did for 2016. It does not mean that they will not start making money and thus increase share price to hopefully reverse the reverses. It is the short sellers who have driven this so low and the lack of a MGuard DE stent. Too bad because they really have a good product and a very poor investor relations PR.
Newbies Oct 10 2016 .08 reverse split 1/25 equals $2 Today .35 equals .014 cents Time for another reverse split? This Co will lose you money Beware
How it's possible that mkt cap is only 2.5M ?! Are they issuing new shares or what!?
NSPR has just seen the last of the selling. Looks like a potential push higher is in store. Yo you should really check out awe-some*sto-cks, they seem on point with their stocks.
MicroCap News Alert: - Startup - Clean Energy Technologies (CETY) buys General Electric “Heat Recovery Systems Division” and within 2 years achieves break-even with sales now set to soar and to be profitable.
CETY announced today the launch of Pacific Rim Initiative with over 20 locations already identified by CETY and PPA power company authorities.
Early orders likely to exceed $25 million in annuitized sales. 12 month target price $.25
CETY/GE proprietary oil-free magnetic levitation turbine technology shatters the competition’s old oil-lubricated screw expander technologies.
Company expects to up list to NASDAQ.
CETY's implementation includes creative lease financing structure, that facilitates rapid adoption and ease of entry with long-term payment structure that allows the utility user to align its investment with actual energy and cost savings realized through use of Clean Cycle™ units," said Kam Mahdi, CEO of CETY.
CETY being welcomed with red carpet to largest markets in the world in need of clean energy.
Clean Energy Technologies (CETY) Launches Pacific Rim Initiative
COSTA MESA, Calif. , Aug. 15, 2017 Clean Energy Technologies, Inc. (OTC: CETY) announced that CETY officially launched its new campaign to deliver its energy solutions to Island Nations utilities at the ...
Why sell this off? The company is about to have triple digit growth and possibly have positive earnings in the 4th quarter. Their statement of double digit growth is very conservative and income can easily double in the next few months as more and more doctors use the CGuard and MGuard resurgence.
WTH is going on with this POS?
TEL AVIV, ISRAEL--(Marketwired - Aug 3, 2017) - InspireMD, Inc. ( NYSE MKT : NSPR ) ( NYSE MKT : NSPR.WS ) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that an endovascular interventional procedure featuring the CGuard™ EPS performed by the team of Dr. Anibal Damonte, Interventional Cardiologist, Director of Interventional Cardiology at the Cardiovascular Institute of Rosario, and Vice President of the Argentine College of Interventional Cardiology, as well as Dr. Maximiliano Rossi, Interventional Cardiologist at the Cardiovascular Institute of Rosario was recorded and broadcast at the SOLACI CACI Congress of Cardiology 2017 (SOLACI CACI '17) in Buenos Aires. The case, entitled "Self Expanding Stent to Avoid Distal Embolization: Carotid InspireMD Stent Case presentation," was displayed to the entire congress.
Need more news and sales projections.
Big disappointment Seriously need big PR surprise or... Original call was right.. Headed to the 30's... 20's... teens Reverse split yet again
No news? Waiting for the 2nd Qtr earnings in Aug. Should be higher sales due to distributor agreements. Why don't they give an estimated projection. The last presentation was almost a month ago.
Craig, Shore things up.
AVGR running up hard
IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
Headed higher Holding shares Looking for 1.50++++
This stock was at $5 back in July '16 why so low now?